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Abstract
Background: In recent years, WHO has made major changes to its guidance on the provision of HIV care and treatment
services. We conducted a longitudinal study from 2013 to 2015 to establish how these changes have been translated into
national policy in Zimbabwe and to measure progress in implementation within local health facilities.
Methods: National HIV programme policy guidelines published between 2003 and 2013 (n = 9) and 2014 and
2015 (n = 5) were reviewed to assess adoption of WHO recommendations on HIV testing services, prevention
of mother-to-child transmission (PMTCT) of HIV, and provision of antiretroviral therapy (ART). Changes in local
implementation of these policies over time were measured in two rounds of a survey conducted at 36 health facilities
in Eastern Zimbabwe in 2013 and 2015.
Results: High levels of adoption of WHO guidance into national policy were recorded, including adoption of
new recommendations made in 2013–2015 to introduce PMTCT Option B+ and to increase the threshold for
ART initiation from CD4≤ 350 cells/mm3 to ≤ 500 cells/mm3. New strategies to implement national HIV policies were
introduced such as the decentralisation of ART services from hospitals to clinics and task-shifting of care from doctors
to nurses. The proportions of health facilities offering free HIV testing and counselling, PMTCT (including Option B+)
and ART services increased substantially from 2013 to 2015, despite reductions in numbers of health workers. Provision
of provider-initiated HIV testing remained consistently high. At least one test-kit stock-out in the prior year was reported
in most facilities (2013: 69%; 2015: 61%; p = 0.44). Stock-outs of first-line ART and prophylactic drugs for opportunistic
infections remained low. Repeat testing for HIV-negative individuals within 3 months decreased (2013: 97%; 2015: 72%;
p = 0.01). Laboratory testing remained low across both survey rounds, despite policy and operational guidelines
to expand coverage of diagnostic services.
Conclusions: Good progress has been made in implementing international guidance on HIV service delivery
in Zimbabwe. Further novel implementation strategies may be needed to achieve the latest targets for
universal ART eligibility.
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Background
The Joint United Nations Programme for HIV/AIDS
(UNAIDS) estimates indicate that, in 2015, there were
36.7 million people living with HIV (PLHIV) world-
wide, of whom 66% lived in sub-Saharan Africa [1].
Antiretroviral therapy (ART) has been shown to be
highly efficacious in reducing mortality, improving the
immunological status of PLHIV and reducing onward
transmission of HIV [2–5]. As evidence of these bene-
fits has grown, WHO recommendations have been re-
vised over time to expand eligibility for ART. Initial
guidance on the scale-up of ART in resource-limited
settings suggested that treatment be initiated for all in-
dividuals with a CD4 count ≤ 200 cells/mm3 or at clin-
ical stages III or IV [6]. In 2010 and 2013, the CD4
count threshold for ART initiation was revised upwards
to ≤ 350 cells/mm3 and ≤ 500 cells/mm3, respectively [7,
8]. Most recently, in 2015, WHO released new guide-
lines recommending ART initiation for all PLHIV re-
gardless of their CD4 cell count or clinical stage [9, 10].
To drive progress in implementing the latest WHO guide-
lines, UNAIDS set the 90–90–90 treatment targets, speci-
fying that 90% of PLHIV should be diagnosed and aware
of their sero-status, 90% of those diagnosed should be re-
ceiving ART and 90% of those on ART should be viro-
logically suppressed by the year 2020 [11].
Generally, countries in sub-Saharan Africa (including
Zimbabwe) and elsewhere have taken up these recom-
mendations and adopted novel strategies to increase up-
take of HIV testing and treatment services [12–14]. Key
strategies have included expansion of prevention of
mother-to-child transmission (PMTCT) programmes and
the introduction of immediate and lifelong ART for all
pregnant and breastfeeding women (Option B+). Other
important health system innovations have included (1) in-
creased use of community-based HIV testing, (2) decen-
tralisation of treatment programmes from hospitals to
clinics, and (3) task-shifting of HIV care from doctors to
nurses [15–18]. These changes, supported by a global ef-
fort to mobilise resources, have succeeded in substantially
increasing uptake of treatment services. By June 2016, ap-
proximately 50% of all PLHIV worldwide were receiving
ART, up from 6.9% in 2005 [1]. However, despite these
changes, many PLHIV continue to initiate ART at low
CD4 cell counts, with advanced clinical symptoms, indica-
tive of AIDS-defining illnesses [19, 20]. Previously, chal-
lenges in the delivery of HIV services have been attributed
to constrained health system infrastructure, primarily in
remote and rural areas. This included insufficient labora-
tory facilities, limited availability of human resources, and
limitations in the availability of drugs and other medical
supplies [18, 21–23]. A 2014 national evaluation of HIV
policy implementation in Zimbabwe found health worker
availability and competence, and the ART supply chain, to
be additional difficulties [24]. All of these factors are likely
to be compounded by the growth in patient numbers as a
result of expanded ART eligibility.
In Zimbabwe, HIV prevalence declined in the early
2000s due to reductions in sexual risk behaviours, lead-
ing to a decrease in HIV incidence and AIDS-related
mortality [25, 26]. HIV prevalence continued to fall
following the introduction of the public sector ART
programme – from 19.2% in 2004 to 14.7% in 2015 [26,
27]. Nevertheless, despite these successes and a major
expansion of the HIV treatment programme in recent
years, only 72% of adults eligible for ART were receiving
treatment at the end of 2015 [24, 28, 29].
Health information systems data and surveys are being
used to track progress towards meeting the UNAIDS tar-
gets. However, in-depth case studies are also needed to
understand the factors facilitating and obstructing progress
towards meeting these targets. In particular, studies are
needed to document how high-level recommendations are
translated into detailed policies and strategies, and to evalu-
ate progress in their implementation at the local level. In
this paper, we use data from policy reviews and health facil-
ity surveys to (1) evaluate changes in national HIV testing
and treatment strategies between 2013 and 2015, and (2) to
measure progress in implementing these policies at local
health facilities in east Zimbabwe over the same time frame.
Policies and strategies considered include those relating to
HIV testing and counselling (HTC), PMTCT, and ART ini-
tiation, retention and patient monitoring.
Methods
Study components and research populations
This study is comprised of two components. We first
perform a review of national policy documents on HIV
care and treatment services in Zimbabwe in 2013 and
updated in 2015. Secondly, we analyse data from two
rounds of a health facility survey in two districts in
Manicaland, Zimbabwe’s eastern province. The survey
was conducted in 2013 and 2015 to measure changes in
implementation of national HIV policies and strategies.
Policy reviews
An initial review of national policies, programme guide-
lines and strategic documentation published between
2003 and 2013 was conducted through a library search
and online collation of policy documents pertaining to
the provision of HTC, PMTCT and ART. The extrac-
tion of policy data was guided by a conceptual frame-
work of indicators influencing the uptake of, and access
to, HIV services developed by the Analysing Longitu-
dinal Population-based data on HIV in Africa (ALPHA)
Network [14, 30] and a set of eight objectives and oper-
ational goals identified as areas of strategic importance
in HIV service delivery by the Zimbabwe Ministry of
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Health and Child Care (Fig. 1) [29]. In 2015, this review
was extended to include documents published in 2014
and 2015. Ministerial departments were approached
where further characterisation of policies was needed.
Policy data, including the policy/strategy prompt/ques-
tion, the documented response, the policy document
year of publication and source, the nature and dates of
any changes in policy over the previous 10 years, and
the presence of any policy conflicts, were abstracted into
an Excel spreadsheet and analysed manually for the
presence or absence of an explicit national policy or im-
plementation strategy [14, 30]. Data were then coded to
capture policy changes for pertinent indicators. Policies
were grouped by service unit (HTC, PMTCT and ART
provision) and by implementation characteristics, namely
(1) service access and coverage, (2) quality of care pro-
vided, (3) co-ordination of care and patient tracking, (4)
support provided to PLHIV, and (5) medical management
of those accessing treatment. These policies were then
compared to WHO recommendations.
Policy implementation at health facilities
To assess levels, patterns and changes in local imple-
mentation of national policies, data were taken from two
rounds of a longitudinal health facility survey. This was
conducted by the Manicaland Centre for Public Health
Research [31] in two predominantly rural administrative
districts in the Manicaland Province (Makoni and Mutasa
District) [31]. The survey included a sub-set of 36 health
facilities selected from a baseline census of all HIV/AIDS
service providers in the study districts. All district and
other major hospitals (n = 5) were included in the sample,
together with random samples of one-third of other types
of health facility (large health centres (LHC) (n = 10),
small health centres and clinics (SHCC) (n = 21)). Each
round of the survey included a face-to-face interview with
the manager or a senior member of staff at each facility
and assessed the availability of human resources at the fa-
cility, the fees for and detailed components of HTC,
PMTCT and ART services provided, the number of pa-
tients receiving care at the institution, and the bottlenecks
perceived to be hindering service delivery.
Data on HIV services from the health facility surveys
were collated and descriptive statistics calculated to esti-
mate the proportion of facilities providing each HIV service
component. For continuous variables, the means, medians
and interquartile ranges were calculated. In the survey,
questions pertaining to the delivery of ART were limited to
those facilities that were ART initiation sites at the time of
data collection. For indicators with missing data, the
Fig. 1 Zimbabwe strategic and operational plan for universal access to HIV services 2013–2017 [29]
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denominator used included only those facilities with data.
Coverage was estimated for all surveyed facilities in the
first instance and later stratified by the type of health facil-
ity (hospitals, LHCs and SHCCs). Comparisons were then
made across the two survey rounds by calculating percent-
age point changes in coverage.
The availability of human resources in 2013 and
2015 was compared by assessing the number of health-
care workers in full-time and part-time employment at
each facility. Healthcare workers were divided into five
groups, namely (1) medical doctors, (2) registered
nurses and midwives, (3) clinical officers, (4) nursing
assistants/nursing aides and (5) laboratory staff. Uptake
of HIV services was estimated by assessing four service
categories, including (1) the number of HIV tests con-
ducted over the previous 3 months, (2) the number of
PMTCT visits recorded over the prior 3 months, (3)
the number of visits made to the health facility by
adult clients for pre-ART monitoring and assessment
over the previous 3 months, and (4) the number of
adult clients receiving first or second line ART at the
health facility. In addition, district-level estimates of
the numbers of healthcare workers and the uptake of
HIV services were generated by weighting the data for
LHCs and SHCCs to allow for the initial sampling of
one-third of these facilities and to account for facilities
with missing data.
To investigate differences in continuous outcome vari-
ables, the paired samples t test was used, assessing the
difference in means between the two survey time points.
Two-sided p values are reported. Differences in propor-
tions were assessed using the McNemar test for corre-
lated proportions to assess changes in the discordant
pairs. Missing data was assumed to be missing com-
pletely at random. A complete case analysis was used in
significance testing and thus only facilities with complete
data for both study rounds were included. ART delivery
proportions were limited to those facilities that provided
ART at the time of the survey. However, in estimating
the mean (adjusted and non-adjusted) number of clients
receiving first- and second-line ART, all facilities were
included. All monetary values are expressed in United
States dollars.
Results
Policy reviews
A total of 10 national policy documents were reviewed
in 2013. These comprised a training manual for an HTC
course [32], the national HTC guidelines for 2005 [33],
technical documentation on PMTCT provision [34], two
community and home-based care guidelines [35, 36], the
patient booklet/care register [37], national guidelines for
tuberculosis (TB) treatment [38], the national essential
medicines registry [39], the chronic HIV care pre-ART
register [40], and guidelines on the use of ART for the
prevention and treatment of HIV in Zimbabwe [12]. In
addition, seven individuals were approached for clarifica-
tion. In the 2015 policy review, five new policy docu-
ments were evaluated, including new guidelines on the
use of ART for the prevention and treatment of HIV
[13], new national guidelines on HTC [41], a policy
document on the integrated management of adolescent
and adult illnesses [42], the Zimbabwe national HIV oper-
ational and service delivery manual [43], and guidelines
for the decentralisation of services for opportunistic infec-
tions (OIs) and ART [44]. In addition, one individual was
approached for further policy clarification.
New national guidelines on the use of ART in
Zimbabwe were released in November 2013, in which two
key changes in national HIV treatment policy were noted.
These were the introduction of Option B+ for PMTCT
and an increase in the CD4 count eligibility threshold for
ART initiation for non-pregnant adults from ≤ 350 cells/
mm3 in 2010 to ≤ 500 cells/mm3 in 2013, both in line with
WHO recommendations [8, 12]. Prior to this, ART eligi-
bility for pregnant women was limited to those in WHO
stage III or IV of HIV disease or a CD4 cell count equal to
or below 350 cells/mm3. Amongst those who were not eli-
gible for ART for their own health, antiretrovirals for
PMTCT were prescribed up to 7 days postpartum [12]. In
addition, the preferred first-line ART regimen for adult
patients which, prior to 2013, was comprised of tenofovir
(TDF) + lamivudine (3TC) + neviripine (NVP), or zidovu-
dine (AZT) + 3TC +NVP, was changed to TDF + 3TC +
efavirenz (EFV)/NVP, in line with the 2013 WHO treat-
ment guidelines [8].
Clinical monitoring is a key component of measuring
an individual’s response to ART. In its 2013 guidelines,
WHO recommended CD4 count testing at ART initi-
ation and 6-monthly thereafter [8]. This was synonym-
ous with the national policies in Zimbabwe in both 2013
and 2015, where 6-monthly CD4 testing was also recom-
mended for those stable on ART. WHO also recom-
mended HIV viral load (VL) testing at 6 months after
initiating ART, and every 12 months thereafter [8]. La-
boratory tests that were desirable, where feasible, were
haemoglobin testing for those initiating AZT, serum cre-
atinine testing for those initiating TDF and an alanine
aminotransferase test for those receiving NVP to evalu-
ate liver function [8], further highlighting the need to
monitor renal function where TDF is used [8]. In
Zimbabwe, a number of national policies and strategies
on the clinical monitoring of PLHIV existed prior to
2013. Laboratory tests that were deemed preferable but
not essential before commencing ART were CD4 cell
count testing, a full blood count for those receiving
AZT, alanine aminotransferase, creatinine test where
TDF is used and chest x-rays to exclude TB infection
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[12]. These similarities indicate a high uptake of WHO
recommendations into Zimbabwe national treatment pol-
icies. In 2013, the Zimbabwe national guidelines changed
to include the use of GeneXpert for TB screening before
ART initiation, syphilis serology testing as well as screen-
ing for hepatitis B and C [13].
Other changes to the Zimbabwe national guidelines
between 2013 and 2015 were the use of targeted repeat
testing for HIV-negative high-risk individuals and the
use of prophylactic isoniazid preventative therapy (IPT)
against TB [13]. In addition, monitoring of ART adher-
ence was introduced into national guidance (including
provision of psychosocial counselling, supply of adherence
cards and the requirement for patients to bring medica-
tions to all visits). National recommendations for the
provision of co-trimoxazole prophylaxis (CTX) remained
unchanged between 2013 and 2015, with CTX suggested
for all patients with WHO stages II, III and IV and those
with CD4 counts of ≤ 350 cells/mm3 [13]. However, this
slightly differed from WHO guidance that recommended
CTX for any WHO stage and CD4 count ≤ 350 cells/mm3,
or WHO stage III and IV irrespective of CD4 [8].
In a 2008 policy update, WHO had recommended
task-shifting as a strategy to increase coverage of HIV
care and treatment services [45]. This was updated in
2013 to allow trained and supervised lay providers –
non-physician clinicians, midwives and nurses – to initi-
ate, distribute and maintain individuals on ART [8]. In
addition, trained and supervised community health workers
could dispense ART between regular clinical visits [8].
Switching of treatment from first- to second-line ART
would continue to be performed by medical doctors. An
explicit policy of multi-tasking and task-shifting of HIV
care was adopted in Zimbabwe in May 2010 [12] and fur-
ther outlined in the Zimbabwe National Strategic Plan for
2011–2015 [46]. New strategies were adopted in July 2013
to implement these policy changes, including increasing
health worker capacity to provide HIV care and treatment
in the form of in-service staff training and improved staff
retention (Fig. 1) [29]. Comprehensive in-service training
activities to improve competence in ART delivery across a
broad range of staff were introduced, and special emphasis
was placed on training nurses for their expanded role in
ART initiation [29]. In addition, the decentralisation of key
HIV activities was supported through strategies to increase
investments in health and community systems and to im-
prove community-based access to services, and services for
key populations were extended (Fig. 1) [29].
Policy implementation at health facilities
The health facilities included in the survey were man-
aged by the Zimbabwe national government (n = 10),
faith-based or private institutions (n = 11), or the rural
district council (n = 15). Between 2013 and 2015, there
were substantial reductions in healthcare workers overall
(Table 1); although there was a slight increase in the
mean number of medical doctors, this was counter-bal-
anced by significant reductions in the mean numbers of
registered nurses (RN) and midwives (2013: 8.72; 2015:
6.47; p = 0.04) and nurse aides (2013: 4.56; 2015: 3.61;
p = 0.04). For RNs and midwives, reductions were seen
across all types of health facility, whilst, for nurse assis-
tants and aides, reductions were found predominantly at
smaller facilities (LHCs and SHCCs) (Table 1). For both
districts combined, weighted numbers of staff within the
five analysis categories were estimated to have fallen
from 788 in 2013 to 570 in 2015. Reductions were found
in the mean numbers of RNs and midwives (2013: 4.37;
2015: 3.23), nursing assistants (2013: 3.41; 2015: 2.29) and
laboratory staff (2013: 0.09; 2015: 0.04). A slight increase
in the mean number of medical doctors was observed, ris-
ing from 0.14 in 2013 to 0.16 in 2015 (Table 3).
HIV testing and counselling
Table 2 summarises the coverage of HTC policy indica-
tors. The proportion of health facilities offering free
HTC increased from 86% in 2013 to 100% in 2015 (p =
0.03). Coverage of provider-initiated counselling and
testing (PITC) for clients accessing antenatal care, TB
and family planning clinics remained consistently high
(≥ 97%) in both surveys. The mean number of HIV tests
conducted per month through PITC increased for ante-
natal care clients (2013: 49.8; 2015: 73.5) and clients in
the out-patient departments (2013: 66.4; 2015: 210.1).
Decreases were observed in PITC testing for TB clients
(2013: 5.3; 2015: 3.26) and clients accessing the sexually
transmitted infections or family planning clinics (2013:
17.5; 2015: 4.2).
Targeted testing offered specifically to sex workers, as
well as the provision of staff training on HTC, remained
marginal. There was a reduction in the proportion of fa-
cilities offering repeated testing after the 3-month win-
dow period for those who had tested HIV negative from
97% in 2013 to 72% in 2014 (p = 0.01); this was particu-
larly pronounced in LHCs and SHCCs (Table 2). Despite
this, counselling provided prior to and after HIV testing
remained high across both survey rounds. Stockouts in
HIV test kits on at least one occasion over the prior year
were reported by a large proportion of facilities, both in
2013 (69%) and in 2015 (61%). The mean duration of
the longest stock-out decreased from 54.5 days in 2013,
to 17.9 days in 2014 (p = 0.0005). This reduction was ob-
served amongst all three types of health facility, with a
decrease of 31.1 days in hospitals, 44.7 days in LHCs
and 36.4 days in SHCCs.
Increases in numbers of HIV tests conducted were found
across all types of health facilities (p = 0.035) (Fig. 2). The
largest mean increase in HTC visits was seen in hospitals
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(2013: 451.3; 2015: 1113.4). Overall, the unadjusted mean
number of HIV testing visits rose from 202.3 in 2013 to
488.9 in 2015. When extrapolated to district level,
weight-adjusted numbers of HTC visits rose from 17,027
in 2013 to 38,735 in 2015, with higher volumes observed
in Mutasa (2013: 9418; 2015: 23,615) than in Makoni
(2013: 7609; 2015: 15,120). Weight-adjusted mean num-
bers of HTC visits per facility rose from 181.1 in 2013 to
421.0 in 2015.
Prevention of mother-to-child transmission (PMTCT) of HIV
In the first round of the survey, coverage of free PMTCT
services was low (44% of health facilities). The median fee
for PMTCT at the 20 facilities that charged for the service
was US$ 10 (range US$ 1–30). By 2015, 97% of facilities of-
fered free PMTCT (the one facility that required payment
charged US$ 11). Progress in the provision of free PMTCT
were found across all types of health facilities (Table 2).
The availability of prophylactic CTX remained high be-
tween the two survey rounds, with marginal improvements
observed within LHCs. The provision of Option B+ and
the WHO recommended PMTCT regimen (TDF + 3TC +
EFV) increased significantly over time (Table 2). Amongst
facilities offering PMTCT services, 79% offered Option B+
in 2013, compared to 100% in 2015 (p = 0.01). Progress in
increasing service coverage was particularly evident at
LHCs where coverage of Option B+ increased from 56% in
2013 to 100% in 2015. Use of the recommended treatment
regimen increased (2013: 18% vs. 2015: 100%) in line with
national treatment policies (Table 2).
Unadjusted estimates of the number of PMTCT visits
recorded in the 3 months prior to each survey showed a
significant increase between 2013 and 2015 (2013: 34.7;
2015: 131.4; p < 0.001), with the largest mean increase
observed amongst hospitals (2013: 73.8; 2015: 340). Dis-
trict estimates for the numbers of PMTCT visits rose
from 2715 in 2013 to 9998 in 2015, whilst means rose
from 27.7 in 2013 to 108.7 in 2015 (Table 3).
Access to antiretroviral therapy, patient retention and
monitoring
The decentralisation of HIV treatment from hospitals to
smaller clinics has led to a high proportion of facilities
offering ART initiation and follow-up in 2015, increasing
from 39% in 2013 to 100% in 2015 (Table 2). ART was
provided freely in 2013, with the limitation, however,
that administration costs could be requested up to a
maximum of US$ 5. In 2015, national policies explicitly
stipulated that HIV/AIDS treatment was free. This pol-
icy alteration was widely implemented amongst surveyed
health facilities, with improvements seen between 2013
and 2015, wherein the provision of free ART rose from
Table 1 Changes in health care staff in 2013 and 2015 in a sample of 36 facilities
2013 2015
N Mean Median Interquartile range N Mean Median Interquartile range p value
Medical Doctors 14 16 0.16
Hospitals 2.6 2 (2–3) 3 3 (2–3)
Large Health Centres 0 0 (0–0) 0 0 (0–0)
Small Health Centres/Clinics 0.05 0 (0–0) 0.05 0 (0–0)
Registered Nurses and Midwives 314 233 0.04
Hospitals 51.4 47 (18–61) 38.2 35 (13–38)
Large Health Centres 2.5 1 (1–3) 1.3 1 (1–2)
Small Health Centres/Clinics 1.52 1 (1–2) 1.38 1 (1–2)
Clinical Officers 1 1 N/A
Hospitals 0.2 0 (0–0) 0.2 0 (0–0)
Large Health Centres 0 0 (0–0) 0 0 (0–0)
Small Health Centres/Clinics 0 0 (0–0) 0 0 (0–0)
Nursing Assistants/Nursing Aides 164 130 0.04
Hospitals 15.8 16 8 16.6 16 (9–19)
Large Health Centres 3.8 3 (2–6) 1.7 1 (1–2)
Small Health Centres/Clinics 2.24 2 (1–3) 1.43 1 (1–2)
Laboratory Staff 5 4 0.57
Hospitals 0.6 1 (0–1) 0.8 1 (1–1)
Large Health Centres 0.2 0 (0–0) 0 0 (0–0)
Small Health Centres/Clinics 0 0 (0–0) 0 0 (0–0)
Tlhajoane et al. Health Research Policy and Systems  (2018) 16:92 Page 6 of 13
Table 2 Coverage of Zimbabwe national policies on HIV testing and counselling (HTC), prevention of mother to child transmission
(PMTCT) and antiretroviral therapy (ART) care in 2013 and 2015
Number of facilities surveyed Total facilities Hospitals Large health centres Small health centres/clinics
2013 2015 2013 2015 2013 2015 2013 2015
36 (100) 36 (100) p value 5 (100) 5 (100) 10 (100) 10 (100) 21 (100) 21 (100)
HTC
Service Access and Coverage
Free HTC services 31 (86) 36 (100) 0.03 5 (100) 5 (100) 8 (80) 10 (100) 18 (86) 21 (100)
PITC to ANC clients 34 (97)a 35 (100)a N/A 5 (100) 5 (100) 10 (100) 10 (100) 19 (95)a 20 (100)a
PITC to TB clients 36 (100) 34 (100)a N/A 5 (100) 5 (100) 10 (100) 9 (100)a 21 (100) 20 (100)a
PITC to STI and FP clients 35 (100)a 35 (100)a N/A 5 (100) 5 (100) 10 (100) 10 (100) 20 (100)a 20 (100)a
Testing offered to sex workers 21 (60)a 21 (58) 0.74 5 (100) 5 (100) 7 (78)a 6 (60) 9 (43) 10 (48)
Occurrence of at least one test-kit stock-out 25 (69) 22 (61) 0.44 5 (100) 4 (80) 7 (70) 4 (40) 13 (62) 14 (67)
Quality of Care
≥ 1 staff member received HTC training in
past 2 years
22 (63)a 18 (50) 0.35 5 (100) 4 (100) 6 (60) 5 (50) 11 (55)a 9 (43)
Quality of care audit at least once a year 32 (91)a 32 (89) 0.71 5 (100) 5 (100) 8 (80) 10 (100) 19 (95)a 19 (81)
Co-ordination of care and patient tracking
Repeat test after 3-month period 35 (97) 26 (72) 0.01 4 (80) 4 (80) 10 (100) 6 (60) 21 (100) 16 (76)
Support to PLHIV
Pre-test counselling always provided 35 (97) 34 (94) 0.56 5 (100) 5 (100) 10 (100) 8 (80) 20 (95) 34 (94)
Post-test counselling always provided 35 (97) 35 (97) N/A 5 (100) 5 (100) 10 (100) 9 (90) 20 (95) 21 (100)
PMTCT
Service Access and Coverage
Free PMTCT services 16 (44) 35 (97) < 0.001 1 (20) 5 (100) 6 (60) 10 (100) 9 (44) 20 (95)
Medical Management
Co-trimoxazole prophylaxis available and in
stock
33 (92) 34 (97)a 0.32 5 (100) 5 (100) 7 (70) 10 (100) 21 (100) 19 (95)a
Option B+ 27 (79)a 35 (100)a 0.01 5 (100) 5 (100) 5 (56)a 10 (100) 17 (85)a 20 (100)a
PMTCT regimen (TDF, 3TC, EFV) 6 (18)a 35 (100)a < 0.001 2 (40) 5 (100) 1 (13)a 9 (100)a 3 (14) 21 (100)
ART and Retention in Care
Service Access and Coverage
Free ART services 29 (81) 36 (100) 0.01 3 (60) 5 (100) 8 (80) 10 (100) 18 (86) 21 (100)
ART initiation at facility 14 (39) 35 (100)a < 0.001 5 (100) 5 (100) 4 (40) 10 (100) 5 (24) 20 (100)a
Quality of Care
Quality of care audit at least once a year 36 (100) 34 (100)a N/A 5 (100) 4 (100)a 10 (100) 10 (100) 21 (100) 20 (100)a
≥ 1 staff member received HIV treatment
training in past 2 years
9 (25) 19 (54)a 0.01 4 (80) 4 (80) 2 (20) 3 (33)a 3 (14) 12 (57)
Co-ordination of care and patient tracking
Drugs collectable by designee 14 (100) 32 (91)a 0.32 5 (100) 5 (100) 4 (100) 10 (100) 5 (100) 17 (85)a
Home visits conducted following poor
adherence
4 (27) 12 (34)a 0.08 1 (20) 3 (60) 1 (25) 6 (60) 1 (20) 14 (70)a
Home visits conducted following missed visit 11 (85)a 10 (29) 0.005 3 (75)a 0 (0) 4 (100) 4 (40) 4 (80) 6 (30)a
Laboratory Testing
Laboratory testing services offered 9 (64)b 9 (26) 0.32 4 (80) 4 (80) 4 (100) 2 (20) 1 (20)b 3 (15)
Liver function tests conducted at facility 1 (7) 1 (3) N/A 1 (20) 1 (20) 0 (0) 0 (0) 0 (0) 0 (0)
Renal function tests conducted at facility 1 (7) 1 (3) N/A 1 (20) 1 (20) 0 (0) 0 (0) 0 (0) 0 (0)
HB/full blood count conducted at facility 7 (50) 7 (20) 0.32 4 (80) 4 (80) 2 (50) 0 (0) 1 (20) 3 (15)
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81% to 100% (p = 0.01). ART service coverage increased,
despite only a modest rise in the proportion of health fa-
cilities reporting that at least one staff member had re-
ceived training in HIV treatment in the previous 2 years
(from 25% in 2013 to 54% in 2015; p = 0.01). All facilities
surveyed in 2013 reported annual audits of their HIV
treatment programme despite there being no explicit na-
tional requirement to do so; however, these were stated
in the national strategic objectives (Fig. 1), where im-
provements in the quality of care and treatment received
by PLHIV is stipulated. Certification processes were out-
lined in the 2015 policy review, which would be under-
taken by district clinical/ART mentorship teams with
quality audits being done on a quarterly basis.
Amongst health facilities offering ART initiation,
coverage of laboratory testing facilities to enable medical
management of PLHIV was low in both rounds, despite
national policy recommendations for tests to be con-
ducted prior to ART initiation and the emphasis placed
on the diagnostic capabilities in the national strategic
and operational plan [25] (Fig. 1). The availability of
CD4 count testing was provided by the same six health
facilities in both rounds, even with the increase in ART
initiation sites. Despite this limited coverage, the propor-
tion of health facilities that reported offering 6-monthly
CD4 counts for PLHIV stable on ART remained consist-
ently high (100%). The provision of liver and renal func-
tion tests remained confined to hospitals only. Coverage
of haemoglobin and full blood count testing was also
partial, with limited availability at LHCs and SHCCs
(Table 2). The continuous availability and supply of
quality HIV treatment diagnostics and medicines was
further assessed through the occurrence of stock-outs of
first-line ART drugs and prophylactic drugs for OIs, spe-
cifically CTX, fluconazole and IPT. This was evaluated
over the 12-month period prior to data collection. The
proportion of facilities that reported at least one
stock-out of first-line ART drugs, such that they could
not provide treatment for patients on ART, remained
consistently low. Only one facility reported at least one
stock-out of first-line ART drugs in 2013, with the lon-
gest stock-out lasting 30 days. No stock-outs of ART
drugs were reported in 2015. Those reporting at least
one stock-out of drugs for OIs over the previous
12 months, such that they could not provide medication,
decreased from 21% in 2013 to 6% in 2015 (Table 2).
Despite national policies on the use of IPT for the pre-
vention of TB, coverage decreased from 79% in 2013 to
43% in 2015 (p = 0.41), falling predominantly within
LHCs and SHCCs.
Amongst strategies to aid the co-ordination of care and
patient tracking activities, national guidelines and policy
documents suggested that ART prescriptions could be
collected by a designated person such as a supporter or
treatment buddy or a family member. Coverage of this im-
plementation strategy was high both in 2013 and 2015, at
100% and 91% of facilities, respectively (p = 0.32). Other
strategies aimed at reducing patient attrition include the
use of home visits following poor adherence and tracing
of those defaulting on treatment (less than 90 days). No
national policies were stipulated with regards to home
visits following poor adherence, however, an increasing
Table 2 Coverage of Zimbabwe national policies on HIV testing and counselling (HTC), prevention of mother to child transmission
(PMTCT) and antiretroviral therapy (ART) care in 2013 and 2015 (Continued)
Number of facilities surveyed Total facilities Hospitals Large health centres Small health centres/clinics
2013 2015 2013 2015 2013 2015 2013 2015
36 (100) 36 (100) p value 5 (100) 5 (100) 10 (100) 10 (100) 21 (100) 21 (100)
CD4 testing conducted at facility 6 (46)a 6 (17) N/A 4 (80) 4 (80) 2 (50) 2 (20) 0 (0)a 0 (0)
Medical Management
Nurse-led ART initiation 10 (71) 32 (100)a 0.08 3 (60) 2 (100)b 3 (75) 10 (100) 4 (80) 20 (100)
WHO-recommended first-line regimen for
non-pregnant adults
9 (64) 33 (94) 0.1 4 (80) 5 (100) 2 (50) 9 (90) 3 (60) 19 (95)
6 monthly (min) CD4 on ART stable patients 14 (100) 35 (100) N/A 5 (100) 5 (100) 4 (100) 10 (100) 5 (100) 20 (100)
Prophylactic IPT in stock 11 (79) 15 (43) 0.41 5 (100) 5 (100) 3 (75) 3 (30) 3 (60) 7 (35)
TB screening at every ART visit 12 (86) 35 (100) 0.16 3 (60) 5 (100) 4 (100) 10 (100) 5 (100) 20 (100)
At least two first-line regimen choices available
at facility
12 (92)a 15 (43) 0.02 5 (100) 2 (40) 2 (67)a 5 (50) 5 (100) 8 (40)
Occurrence of at least one stock-out of first-
line ART drugs
1 (7) 0 (0)a N/A 0 (0) 0 (0) 0 (0) 0 (0) 1 (20) 0 (0)
Occurrence of at least one stock-out of OI drugs 4 (21) 2 (6) 0.65 0 (0) 1 (20) 2 (50) 0 (0) 1 (20) 1 (5)
3TC lamivudine, ANC antenatal care, EFV efavirenz, FP family planning, HB haemoglobin, IPT isoniazid preventative therapy, OI opportunistic infection, PITC
provider-initiated testing and counselling, PLHIV people living with HIV, STI sexually transmitted infection, TB tuberculosis, TDF tenofovir
aUnder 10% data missing
bOver 10% data missing
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Fig. 2 Uptake of HIV services across different types of health facilities in Eastern Zimbabwe. Sample sizes (n): 2013: HIV Testing: Hospitals (n = 4),
LHC (n = 10), SHC (n = 20); PMTCT: Hospitals (n = 5), LHC (n = 10), SHC (n = 21); Pre-ART: Hospitals (n = 1), LHC (n = 6), SHC (n = 16); ART: Hospitals
(n = 5), LHC (n = 9), SHC (n = 19). 2015: HIV Testing: Hospitals (n = 5), LHC (n = 10), SHC (n = 19); PMTCT: Hospitals (n = 5), LHC (n = 10), SHC (n = 19);
Pre-ART: Hospitals (n = 5), LHC (n = 10), SHC (n = 20); ART: Hospitals (n = 5), LHC (n = 10), SHC (n = 20). Open circles in the box plots represent outliers.
a For those receiving ART, all facilities were included in 2013, including those that were not yet delivering ART
Table 3 District estimates of HIV service uptake and human resources
Total facilities Mutasaa Makonia
2013 2015 2013 2015 2013 2015
N Mean N Mean N Mean N Mean N Mean N Mean
Uptake of HIV services
HIV Testing and Counselling 17,027 181.1 38,735 421 9418 188.4 23,615 524.8 7609 172.9 15,120 321.7
PMTCT 2715 27.7 9998 108.7 1113 21.8 3299 73.3 1899 40.4 6699 142.5
Pre-ART care 9705 144.9 18,132 190.9 4479 93.3 7432 154.8 5226 275.1 12,422 264.3
ART 6310 123.7 9789 191.9 6310 123.7 9789 191.9 5911 125.8 12,438 264.6
Human resources
Medical Doctors 14 0.14 16 0.16 8 0.16 9 0.18 6 0.13 7 0.15
Registered Nurses and Midwives 428 4.37 317 3.23 213 4.18 137 2.69 215 4.57 180 3.83
Clinical Officers 1 0.01 1 0.01 1 0.02 1 0.02 0 0 0 0
Nursing assistants and aides 334 3.41 224 2.29 189 3.71 137 2.69 145 3.09 87 1.85
Laboratory staff 9 0.09 4 0.04 6 0.12 3 0.06 3 0.06 1 0.02
aDistrict population estimates from 2012 national census: Mutasa: 168,747, Makoni: 272,340 [47]
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proportion of facilities used this strategy, rising from 27%
in 2013 to 34% in 2015 (p = 0.08). The use of village health
workers through community outreach initiatives was en-
couraged in 2013 to trace defaulters and home visits were
stipulated in 2015; however, coverage fell over the two sur-
vey periods (2013: 85%; 2015: 29%; p = 0.005), especially
amongst hospitals (Table 2).
The explicit policies and strategies for multi-tasking and
task-shifting for ART initiation, as previously mentioned,
translated into an increase in coverage of nurse-led ART
initiation amongst the surveyed health facilities from 71%
in 2013 to 100% in 2015 (p = 0.08). The proportion of facil-
ities offering the WHO recommended first-line ART regi-
men for non-pregnant adults also increased from 64% in
2013 to 94% in 2015 (p = 0.1); however, availability of at
least two first-line ART choices decreased from 92% in
2013 to 43% in 2015 (p = 0.02), suggesting that difficulties
may be encountered should stock-outs occur. Routine
screening for TB amongst PLHIV is explicitly stated in na-
tional policy documents and coverage remained high within
health facilities (Table 2), despite a growth in the number of
PLHIV enrolled in care between 2013 and 2015.
Unweighted estimates of the mean number of pre-
ART visits across all surveyed health facilities increased
from 144 in 2013 to 281 in 2015 (p = 0.68), with the
largest increases observed amongst hospitals (Fig. 2).
Weight-adjusted estimates of district level changes in
the number of pre-ART visits showed an overall increase
from 9705 in 2013 to 18,132 in 2015. Increases were
higher in Makoni district (2013: 5226; 2015: 12422)
compared to Mutasa (2013: 4479; 2015: 7432). The ad-
justed mean number of pre-ART visits per facility in-
creased from 144.9 in 2013 to 190.9 in 2015.
The average number of clients receiving first- or
second-line ART increased overall (2013: 244.15; 2015:
286.9; p = 0.2). When stratified by health facility type, the
largest increase was observed within SHCCs (2013: 55.6;
2015: 183.2), followed by LHCs (2013: 127.4; 2015 241.4).
The mean number of ART clients fell in hospitals from
1121.8 in 2013 to 793.2 in 2015. The total estimated num-
ber of ART clients in the two districts rose from 12,221 in
2013 to 22,197 in 2015; rising more prominently in
Makoni district (increase of 6527) than in Mutasa district
(increase of 3479). District estimates for the mean num-
bers of clients per facility increased from 137.3 in 2013 to
233.7 in 2015 (Table 3) [47].
Discussion
In a review of national HIV care and treatment guide-
lines in Zimbabwe, we found high uptake of WHO
recommendations adopted into national policy. New na-
tional HIV treatment guidelines were produced in
Zimbabwe in November 2013 following the release of
new WHO recommendations in June 2013. Changes
adopted included an increase in the CD4 count thresh-
old for ART eligibility, the introduction of Option B+, and
a change in the recommended first-line ART regimen. Be-
tween 2013 and 2015, we found evidence of increases in
implementation of pre-existing and new national policies
at facility level over time. Notable improvements included
increases in the proportions of health centres offering free
HTC, PMTCT and ART services, increased coverage of
Option B+, and use of the latest WHO recommended reg-
imens for pregnant women and non-pregnant adults.
For some indicators, service provision went beyond the
standards outlined in explicit policies (e.g. annual quality
of care audits and, at some facilities, home visits in cases
of poor ART adherence), whilst, for a few others, imple-
mentation remained low or decreased (e.g. gaps in the
availability of prophylactic IPT and in coverage of pre-
ART initiation laboratory tests), despite the emphasis on
strengthening local diagnostic capabilities within the na-
tional strategic objectives [29]. Our results also highlighted
the existence of implementation gaps in the availability
and stocking of at least two first-line ART regimen
choices. Whilst the WHO-recommended first-line ART
regimen of TDF + 3TC + EFV/NVP has been adopted into
Zimbabwe national guidelines, the limited availability of
different regimen choices may provide challenges in the
provision of ART should stock-outs occur or alternate reg-
imens be required. Similar findings on stock-outs within
public and private sector ART sites from all administrative
districts in Zimbabwe have been reported, where only
18.9% of sites included reported no ART stock-outs for
adult treatment regimens [48]. Similarly, the gaps ob-
served in the provision of prophylactic medicines such as
CTX and IPT are of concern as adequate supply chain
management has been identified as a bottleneck in the
provision of ART [24].
We found that the general improvements in service
provision at the facility level translated into large in-
creases in the numbers of visits made by clients for HIV
testing and treatment services. This picture is supported
by data from a longitudinal general population open cohort
survey in the same study districts in Manicaland province,
showing steady improvements in all stages of the treatment
cascade between 2008 and 2013 [49]. Strategies that may
have contributed to increases in facility implementation in-
clude decentralisation of services to more rural facilities,
nurse-led ART initiation, and increased training of health
workers in the provision of HIV care and treatment. These
strategies appear to have been implemented successfully in
east Zimbabwe, despite substantial reductions in numbers
of health workers. One factor that may have contributed to
this is the results-based funding (RBF) system – a health
system financing strategy based on performance and out-
puts at facility level – that was introduced in Zimbabwe in
2011. The RBF system is aimed particularly at improving
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service delivery at rural outposts [50]. Although not ini-
tially aimed specifically at improving HIV services, the
availability of additional funds and overall strengthening of
the health system may have played a role in enhancing
these services [51].
Whilst it is known that multiple sources exist, including
RBF and the country’s own internally funded National
AIDS Trust Fund [52], and that resources generally have
been severely constrained by the continued weakness of
the national economy, this study did not investigate fund-
ing streams for HIV and other health programmes in
Zimbabwe. However, detailed research on specific uses of
different funding streams at the facility level could be
beneficial to identify means to address the gaps in policy
implementation highlighted in this study. Particular atten-
tion could be paid to investigating the priorities and activ-
ities set by non-governmental organisations and external
donors, and their influence on patterns of implementa-
tion. In a 2017 analysis assessing policy implementation
across two Health and Surveillance Sites in Uganda [48],
key informants revealed the need for commitments from
external partners to provide the resources required to sup-
port implementation; such issues may be a concern in
Zimbabwe as well, thus warranting further investigation.
Progress with implementation of national HIV policies
has also been evaluated in a cross-sectional study of six
health facilities in Karonga, Malawi, in December 2013
[53, 54]. Free HTC, PMTCT and ART services were pro-
vided at all facilities and Option B+ was available in 90%
of facilities, suggesting slightly earlier implementation of
these services in Malawi compared to east Zimbabwe.
The later implementation of updated HIV services found
in east Zimbabwe compared to some of the sites in other
countries may be due, in part, to the economic difficulties
that the country continues to face following the economic
collapse in 2009 [55]. For example, these economic diffi-
culties may have contributed to the falling numbers of
health workers we observed in this study. However, in
general, our findings for east Zimbabwe fit a wider pattern
of substantial overall progress in adoption and implementa-
tion of WHO recommendations on HIV testing and treat-
ment services, albeit with some important gaps remaining
(e.g. services for high-risk groups) [56].
Prior to the scale-up of ART services from the mid-
2000s, Zimbabwe experienced an earlier and larger re-
duction in HIV prevalence [25, 26] compared to neigh-
bouring countries such as Botswana and South Africa.
This relative success was achieved during a period of
limited external donor support and has been attributed
primarily to spontaneous local responses to high AIDS
mortality backed up by effective national HIV prevention
programmes [25]. In contrast, the scale-up of ART ser-
vices in Zimbabwe has received greater donor support,
with donor funds accounting for 75–100% of the total
HIV/AIDS budget in 2013 [14], much higher than in South
Africa, for example, where the equivalent figure was 0–24%
[14]. External partners may be more willing to take up new
strategies to expand the provision of HIV care and treat-
ment services than national governments, which may be
more parsimonious. Possibly as a consequence, as we docu-
ment here, national ART policies in Zimbabwe have largely
followed, and sometimes have surpassed, WHO recom-
mendations. Examples of the latter include the early adop-
tion of home-based care policies [57] and introduction of
services for anonymous HTC, training for healthcare staff
and patient tracking following ART initiation [14].
In December 2016 – subsequent to the period covered
by the current study – the Government of Zimbabwe
adopted the new WHO guidance recommending ART ini-
tiation for all HIV-positive individuals regardless of CD4
count or clinical stage and the UNAIDS 90–90–90 targets.
To achieve these new targets and to address pre-existing
gaps in policy implementation, more innovative strategies
for service implementation will be needed. Current initia-
tives in Manicaland and in other parts of Zimbabwe in-
clude revival of health centre committees to increase
community involvement, mobile HIV testing, and index
case-based HIV testing. Other strategies that could be ex-
tended or are being piloted and could be effective include
HIV self-testing [58, 59] and home visits for people with
poor ARTadherence. Policies pertaining to retention of pa-
tients in care and innovative strategies to improve patient
monitoring will be important for achieving high levels of
virological suppression – the last of UNAIDS 90–90–90
treatment goals. One key component that will be needed
is VL monitoring to allow for timely detection of treat-
ment failure. Despite the recent introduction of VL moni-
toring into national policy in a number of countries in
sub-Saharan Africa, implementation of VL monitoring re-
mains limited and is targeted largely towards high risk in-
dividuals [60, 61]. Previous studies have found higher
rates of switching to second-line ART amongst individuals
in Uganda and in Zimbabwe that received both clinical
and laboratory monitoring, as opposed to laboratory mon-
itoring alone [62]. This highlights the importance of na-
tional policies aimed at improving patient monitoring
coupled with providing innovative methods of service de-
livery both in and out of the health facilities to further de-
centralise services, particularly laboratory services, to limit
patient attrition.
Limitations of this study include missing data for
some indicators of policy implementation (as indicated
in Table 2), which may distort the comparison between
time periods as a complete case analysis was used to
generate statistical estimates. Furthermore, the study
was conducted in two predominantly rural districts of
Manicaland, which is currently the province with the
lowest HIV prevalence in Zimbabwe [63].
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Conclusion
Through the progressive uptake of WHO recommenda-
tions for ART initiation into national HIV care and treat-
ment policies, coverage of PMTCT Option B+ and ART
use has increased in Zimbabwe between 2013 and 2015.
This may be due not only to extensions in ART eligibility
but also to implementation of key strategies, including the
decentralisation of service provision from hospitals to
clinics located closer and within communities and task-
shifting of HIV care to lower-level cadres of healthcare
workers within the health system. Coverage of PITC initia-
tives has been consistently high, although specific provision
for high-risk groups, such as men who have sex with men,
remains limited. Whilst many facilities continued to pro-
vide mobile testing and outreach services, laboratory moni-
toring remained confined to larger hospitals. As the
population of individuals requiring HIV services is pro-
jected to grow, further innovative service delivery strategies
may be needed to improve linkage to care and to reduce
losses to clinical follow-up. Community-based interven-
tions, such as self-testing and home-based ART initiation,
and clinical monitoring may be beneficial in achieving 90–
90–90 treatment targets.
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